Personalized Medicine for Diabetes

Klonoff, David C.

doi:10.1177/193229680800200301

Cited by 51 publications

(39 citation statements)

References 76 publications

(66 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3,4 We will explore current data regarding the use of CGM in T2D and the importance of a standardized glucose report as part of a shared decision-making (SDM) encounter.…”

mentioning

confidence: 99%

Clinical Use of Continuous Glucose Monitoring in Adults with Type 2 Diabetes

Carlson¹,

Mullen²,

Bergenstal³

2017

Diabetes Technology & Therapeutics

136

100

View full text Add to dashboard Cite

Background: Hemoglobin A1c is an excellent population health measure for the risk of vascular complications in diabetes, while continuous glucose monitoring (CGM) is a tool to help personalize a diabetes treatment plan. The value of CGM in individuals with type 1 diabetes (T1D) has been well demonstrated when compared with utilizing self-monitoring of blood glucose (SMBG) to guide treatment decisions.CGM is a tool for patients and clinicians to visualize the important role that diet, exercise, stress management, and the appropriate selection of diabetes medications can have in managing type 2 diabetes (T2D). Several diabetes organizations have recently reviewed the literature on the appropriate use of CGM in diabetes management and concluded CGM may be a useful educational and management tool particularly for patients on insulin therapy. The indications for using CGM either as a clinic-based loaner distribution model for intermittent use (professional CGM) or a CGM system owned by the patient and used at home with real-time glucose reading (personal CGM) are only beginning to be addressed in T2D. Most summaries of CGM studies conclude that having a standardized glucose pattern report, such as the ambulatory glucose profile (AGP) report, should help facilitate effective shared decision-making sessions.The future of CGM indications for the use of CGM is evolving rapidly. In some instances, CGM is now approved for making medication adjustments without SMBG confirmation and it appears that some forms of CGM will be approved for use in the Medicare population in the United States in the near future. Many individuals with T1D and T2D and their care teams will come to depend on CGM as a key tool for diabetes management.

show abstract

“…3,4 We will explore current data regarding the use of CGM in T2D and the importance of a standardized glucose report as part of a shared decision-making (SDM) encounter.…”

mentioning

confidence: 99%

Clinical Use of Continuous Glucose Monitoring in Adults with Type 2 Diabetes

Carlson¹,

Mullen²,

Bergenstal³

2017

Diabetes Technology & Therapeutics

136

100

View full text Add to dashboard Cite

show abstract

“…In this article we focus on personalization of diabetes treatment rather than on all strategies of Personalized Medicine for Diabetes (PMFD), because widespread adoption of this global approach will only occur when the identification of risk factors through genotype or through biomarkers is accompanied by an effective therapy [26]. PMFD uses information about the genetic makeup of a person with diabetes to customize strategies for preventing, detecting, treating and monitoring their diabetes.…”

Section: Personalization Of Diabetes Therapymentioning

confidence: 99%

Towards Personalization of Diabetes Therapy Using Computerized Decision Support and Machine Learning: Some Open Problems and Challenges

Donsa

Spat

Beck

et al. 2015

Lecture Notes in Computer Science

View full text Add to dashboard Cite

Abstract. Diabetes mellitus (DM) is a growing global disease which highly affects the individual patient and represents a global health burden with financial impact on national health care systems. Type 1 DM can only be treated with insulin, whereas for patients with type 2 DM a wide range of therapeutic options are available. These options include lifestyle changes such as change of diet and an increase of physical activity, but also administration of oral or injectable antidiabetic drugs. The diabetes therapy, especially with insulin, is complex. Therapy decisions include various medical and life-style related information. Computerized decision support systems (CDSS) aim to improve the treatment process in patient's self-management but also in institutional care. Therefore, the personalization of the patient's diabetes treatment is possible at different levels. It can provide medication support and therapy control, which aid to correctly estimate the personal medication requirements and improves the adherence to therapy goals. It also supports long-term disease management, aiming to develop a personalization of care according to the patient's risk stratification. Personalization of therapy is also facilitated by using new therapy aids like food and activity recognition systems, lifestyle support tools and pattern recognition for insulin therapy optimization. In this work we cover relevant parameters to personalize diabetes therapy, how CDSS can support the therapy process and the role of machine learning in this context. Moreover, we identify open problems and challenges for the personalization of diabetes therapy with focus on decision support systems and machine learning technology.

show abstract

“…Personalized medicine refers to determining specific information about a patient and then prescribing a treatment that is specific for that patient. Personalized medicine involves defining disease subtypes and defining biomarkers that can identify which patients who are most likely to benefit from a specific treatment (19). It is just the addition of data mining to improved genomic analyses leading to the new term "precision medicine" (20).…”

Section: Precision Medicinementioning

confidence: 99%

Migraine in the era of precision medicine

Zhang

Dong

Yu³

2016

Ann. Transl. Med.

View full text Add to dashboard Cite

Migraine is a common neurovascular disorder in the neurologic clinics whose mechanisms have been explored for several years. The aura has been considered to be attributed to cortical spreading depression (CSD) and dysfunction of the trigeminovascular system is the key factor that has been considered in the pathogenesis of migraine pain. Moreover, three genes (CACNA1A, ATP1A2, and SCN1A) have come from studies performed in individuals with familial hemiplegic migraine (FHM), a monogenic form of migraine with aura. Therapies targeting on the neuropeptids and genes may be helpful in the precision medicine of migraineurs. 5-hydroxytryptamine (5-HT) receptor agonists and calcitonin gene-related peptide (CGRP) receptor antagonists have demonstrated efficacy in the acute specific treatment of migraine attacks. Therefore, ongoing and future efforts to find new vulnerabilities of migraine, unravel the complexity of drug therapy, and perform biomarker-driven clinical trials are necessary to improve outcomes for patients with migraine.

show abstract

Personalized Medicine for Diabetes

Cited by 51 publications

References 76 publications

Clinical Use of Continuous Glucose Monitoring in Adults with Type 2 Diabetes

Clinical Use of Continuous Glucose Monitoring in Adults with Type 2 Diabetes

Towards Personalization of Diabetes Therapy Using Computerized Decision Support and Machine Learning: Some Open Problems and Challenges

Migraine in the era of precision medicine

Contact Info

Product

Resources

About